- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01005537
Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma
Single Patient Study to Evaluate Cellular Adoptive Immunotherapy Using Autologous Lymphocytes Following Cyclophosphamide Conditioning for a Single Patient With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Biological therapy, such as cellular adoptive immunotherapy using autologous lymphocytes, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the lymphocytes to kill tumor cells. Giving cyclophosphamide together with autologous lymphocytes and aldesleukin may be an effective treatment for metastatic melanoma.
PURPOSE: This phase I/II trial is studying the side effects of giving cyclophosphamide together with autologous lymphocytes and aldesleukin and to see how well it works in treating patients with metastatic melanoma.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
Primary
- Assess the safety and toxicity of cellular adoptive immunotherapy with autologous tumor-infiltrating lymphocytes (TIL) following cyclophosphamide conditioning and post-infusion aldesleukin (IL-2) in patients with metastatic melanoma.
- Assess the duration of in vivo persistence of adoptively transferred lymphocytes.
Secondary
- Evaluate the antitumor effect of adoptively transferred autologous TIL following cyclophosphamide conditioning and post-infusion IL-2 in these patients.
OUTLINE: Patients receive cyclophosphamide IV on days -3 and -2 and autologous tumor-infiltrating lymphocytes (TIL) IV on day 0. Beginning 6 hours after TIL infusion, patients receive high-dose aldesleukin (IL-2) IV three times daily on days 0-5 (for up to 14 doses) OR low-dose IL-2 subcutaneously twice daily on days 0-14 (for up to 28 doses). Patients may then receive two additional courses of TILs and low-dose IL-2 (with or without cyclophosphamide), if indicated.
After completion of study treatment, patients are followed up periodically.
Undersøgelsestype
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
- Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease.
- 18 to 75 years of age and able to tolerate high-dose cyclophosphamide
- Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic imaging (X-ray, CT scan).
- For patients receiving HD-IL-2, normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal ECG, any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension.
For leukapheresis, patients must meet the following criteria (any exceptions to this will require prior approval by the Apheresis director and Principal Investigator):
- Pulse: >45 or < 120
- Weight: >45 kg
- Temperature: <38C (<100.4 F)
- WBC: >3,000
- HCT: >30%
- Platelets: >100,000
- ADDITIONAL INCLUSION CRITERIA FOR T CELL INFUSION
Exclusion Criteria
Significant cardiovascular abnormalities as defined by any one of the following:
- congestive heart failure,
- clinically significant hypotension,
- symptoms of coronary artery disease,
- presence of cardiac arrhythmias on EKG requiring drug therapy
- ejection fraction < 50 % (echocardiogram or MUGA)
- Patients with active infections or oral temperature > 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Cassian Yee, MD, Fred Hutchinson Cancer Center
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer efter histologisk type
- Neoplasmer
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Neuroendokrine tumorer
- Nevi og melanomer
- Melanom
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Anti-HIV-midler
- Anti-retrovirale midler
- Antirheumatiske midler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Myeloablative agonister
- Aldesleukin
- Cyclofosfamid
Andre undersøgelses-id-numre
- 2355.00
- P30CA015704 (U.S. NIH-bevilling/kontrakt)
- FHCRC-2355.00
- IR-6984
- CDR0000648071 (Registry Identifier: PDQ)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Melanom (hud)
-
Alma LasersTrukket tilbageSkin ResurfacingForenede Stater
-
R2 DermatologyAfsluttet
-
Syneron MedicalAfsluttetSkin Resurfacing | RynkereduktionForenede Stater, Canada
-
University of Split, School of MedicineAfsluttetSkin Recovery i forskellige humane hudskademodellerKroatien
-
National Cancer Institute (NCI)ExelisisAfsluttetStage IV Uveal Melanoma AJCC v7 | Tilbagevendende uveal melanom | Stage III Uveal Melanoma AJCC v7 | Stage IIIA Uveal Melanoma AJCC v7 | Stadie IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7Forenede Stater, Canada
-
Centre Hospitalier le MansRekruttering
-
The First Affiliated Hospital of Dalian Medical...UkendtSår og skader | Trauma | Brud, åben | Skin ExpanderKina
-
Integrative Skin Science and ResearchBurt's Bees Inc.RekrutteringAcne | Skin MicroboimeForenede Stater
-
National Cancer Institute (NCI)AfsluttetFase IV kutan melanom AJCC v6 og v7 | Tilbagevendende melanom | Fase IIIC kutan melanom AJCC v7 | Slimhinde melanom | Iris melanom | Fase IIIA kutan melanom AJCC v7 | Fase IIIB kutan melanom AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanom | Tilbagevendende uveal melanom | Stage IIIA Uveal Melanoma AJCC v7 og andre forholdForenede Stater
-
PT. Daewoong InfionEquilab InternationalAfsluttetHudtransplantatar | Split-Thickness Skin Graft (STSG)Indonesien
Kliniske forsøg med cyclophosphamid
-
Children's Hospital Los AngelesLucile Packard Children's HospitalAfsluttetMetaboliske sygdomme | Stamcelletransplantation | Kronisk granulomatøs sygdom | Knoglemarvstransplantation | Thalassæmi | Wiskott-Aldrich syndrom | Genetiske sygdomme | Perifer blodstamcelletransplantation | Pædiatri | Diamond-Blackfan Anæmi | Allogen Transplantation | Kombineret immundefekt | X-bundet lymfoproliferativ...
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... og andre samarbejdspartnereAfsluttetAnæmi, aplastiskForenede Stater
-
Centre Oscar LambretAfsluttet
-
Institut BergoniéMerck Sharp & Dohme LLC; National Cancer Institute, France; Transgene; Fondation...RekrutteringBrystkræft | Blødt væv sarkom | Faste tumorerFrankrig
-
Columbia UniversityUkendtAlvorlig kombineret immundefekt | Fanconi Anæmi | Knoglemarvssvigt | OsteopetroseForenede Stater
-
Shandong Cancer Hospital and InstituteUkendt
-
Mahidol UniversityAfsluttetNyreinsufficiens | InfektionThailand
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1AfsluttetHepatocellulært karcinomBelgien, Tyskland, Italien, Spanien, Det Forenede Kongerige
-
University of Turin, ItalyUkendt
-
Tao OUYANGAfsluttet